COVID-19 and IBD Webinar 01 May 2020 Rules of engagement Please - - PowerPoint PPT Presentation

COVID-19 and IBD Webinar

01 May 2020

Rules of engagement

• Please remember to mute your phone or computer when you are not

speaking

• If you want to make a comment or ask a question, please enter a

notification in the chat box

• We need to stay on time
• Please try to hold comments and questions until the end of each

presentation

• We’ll likely need to cut off comments and questions to keep moving

Agenda 01 May 2020

8:00am – 8:05am Welcome Maria Abreu 8:05am - 8:15am IOIBD Gives project Gil Kaplan 08:15am-08:25am Stride-II project update Dan Turner 8:25am - 8:30am Update Task Force ‘Research’ Dermot McGovern 8:30am - 8:35am Update Task Force ‘Telehealth’ Uma Mahadevan 8:35am – 8:40am Update Task Force ‘Recommendations’ Corey Siegel 8:40 am – 8:45am Update publications Corey Siegel, Feza Remzi 8:45am - 08:50am JCC online publication, together with ECCO Maria Abreu, Laurent Peyrin-Biroulet 8:50am - 08:55am AGA University, FDA Letter Maria Abreu 08:55am-09:00am Any other business + Closing Maria Abreu

IO IOIB IBD GIV IVES PROJECT Gil il Kaplan

IO IOIBD GIV IVES: Glo lobal l IB IBD Vis isualization of Epid idemiology Studies (GIV IVES)

• Funded by a pilot grant by IOIBD: Globalization Cluster
• Collaboration: Siew Ng, Richard Geary,
• 1. Systematic review of population-based studies of burden of IBD
• Incidence & Prevalence
• Hospitalization, Surgery
• Analytics: Data visualizations, pooling, temporal trends, forecasting
• 2. Interactive atlas for users to share maps and graphs on the epidemiology
• f IBD using ArcGIS
• 3. Updating data synthesis and review on a regular basis
• Published manuscripts periodically (static map – snapshot in time)
• Data updated continuously (dynamic map – real-time data)

https://ucalgary.maps.arcgis.com/apps/MapSeries/index.h tml?appid=93e520cd04624e128f7acbb238f7ef87

Governance and Future Studies

Governance • Gil Kaplan, Siew Ng, Richard Gearry IOIBD Members

• Country +/- Regional Custodian
• Verification, Updating, identify and oversee affiliate custodian

IOIBD Affiliate

• Country Custodian
• Non-members – verification, updating
• Carry out research in gap countries

Next Step: Data Verification (Excel Sheet and PDF Folder)

STRIDE II II update Dan Turner

Powered by

STRIDE-II: a position paper from IOIBD on targets of IBD Treatment

Results of f th the 1st voting round

Results of the second voting round

10 20 30 40 50 60 70 80 90 100 Clinical remission is a target Measures to explore MH Histology is not a target TH is not a target Disability and QOL are targets Fatiue is a target Depression and anxiety are targets Agree with the figure

Updates Taskforce groups

IOIBD COVID-19 RESEARCH TASKFORCE

DERMOT, GIL, IRIS, SEVERINE, ARIE, VINEET, BRITTA, FLAVIO, ZHIHUA, BALFOUR, DAVID, WALTER, MATTHIEU

IOIBD COVID-19 RESEARCH TASKFORCE

DERMOT, GIL, IRIS, SEVERINE, ARIE, VINEET, BRITTA, FLAVIO, ZHIHUA, BALFOUR, DAVID, WALTER, MATTHIEU

ADDITIONAL SUGGESTIONS FROM IOIBD – THANK YOU!

DERMOT, GIL, IRIS, SEVERINE, ARIE, VINEET, BRITTA, FLAVIO, ZHIHUA, BALFOUR, DAVID, WALTER, MATTHIEU

• Carriage of virus in gut epithelium / stool and impact on endoscopy processing stool

samples etc. What about the risk of infection of colonoscopy?

• Re-initiating IBD treatment in IBD patients resolving COVID-19
• What explains the very low incidence of COVID-19 in children? Is it subclinical infection
• r do they not acquire SARS-COV2? Could assessment of stool and NP cultures for

SARS-COV2 (and serology) of children help answer this?

• Is nontoxic U-V lighting in endoscopy and other procedure suites something to think

about?

• When to restart medications following COVID-19
• Are patients receiving immunosuppressant medications and who work in healthcare at

greater risk of developing COVID-19 than healthcare workers without IBD or with IBD

• n no immunosuppressant medications.
• How safe are mesalamine medications in terms of COVID-19 outcomes
• Which dose of prednisone/solone is a significant risk?

IOIBD COVID-19 RESEARCH TASKFORCE

DERMOT, GIL, IRIS, SEVERINE, ARIE, VINEET, BRITTA, FLAVIO, ZHIHUA, BALFOUR, DAVID, WALTER, MATTHIEU

Next Steps

• Manuscript
• Designed around table and text referring to table
• Appendix – ‘consensus data collection form’
• RAND-type data collection from IOIBD etc on

priorities

• Research Proposal Structures/Protocols
• Serology registry/biobank
• Gut Epithelium and virus
• Stool
• ‘Speed dating’ for COVID-19 IBD research

Telehealth

Uma Mahadevan, Charlie Lees, Miguel Regueiro, Ailsa Hart, Pia Munkholm

Deliverables

• Telehealth paper for JCC with best practices table for website
• Completed. With publications committee
• Telehealth survey
• 754 respondents in 54 countries
• Commentary for Gastroenterology
• In process

IOIBD telemedicine and IBD survey

N=754 82.4% are gastroenterologists 10.1% are IBD specialist nurses 4.1% are surgeons

Algeria; 0; 0% Argentina; 3; 0% Australia; 18; 2% Austria; 1; 0% Belgium; 15; 2% Brazil; 43; 6% Bulgaria; 1; 0% Canada; 23; 3% Chile; 1; 0% China; 22; 3% Colombia; 6; 1% Costa Rica; 2; 0% Croatia; 3; 0% Czech Republic; 3; 0% Denmark; 25; 3% Egypt; 5; 1% Estoni a; 1; 0% Faroe Islands; 1; 0% France; 3; 0% Germany; 6; 1% Greece; 21; 3% Hong Kong; 8; 1% Hungary; 2; 0% India; 28; 4% Ireland; 19; 3% Israel; 36; 5% Italy; 78; 10% Japan; 7; 1% Korea, Republic of; 5; 1% Kuwait; 17; 2% Lebanon; 16; 2% Lithuania; 1; 0% Malaysia; 3; 0% Malta; 1; 0% Moldova, Republic of; 1; 0% Netherlands; 5; 1% New Zealand; 28; 4% Niger; 1; 0% Nigeria; 1; 0% Norway; 12; 2% Poland; 1; 0% Portugal; 2; 0% Romania; 25; 3% San Marino; 1; 0% Saudi Arabia; 17; 2% Slovenia; 1; 0% South Africa; 6; 1% Spain; 23; 3% Sweden; 14; 2% Switzerland; 2; 0% Turkey; 3; 0% United Arab Emirates; 4; 1% United Kingdom; 90; 12% United States; 83; 11%

United Kingdom 90 United States 83 Italy 78 Brazil 43 Israel 36 India 28 New Zealand 28 Denmark 25 Romania 25 Canada 23 Spain 23 China 22 Greece 21 Ireland 19 Australia 18 Kuwait 17 Saudi Arabia 17 Lebanon 16 Belgium 15 Sweden 14 Norway 12 Hong Kong 8 Japan 7 Colombia 6 Germany 6 South Africa 6 Egypt 5 Korea, Republic of 5 Netherlands 5 United Arab Emirates 4 Argentina 3 Croatia 3 Czech Republic 3 France 3 Malaysia 3 Turkey 3 Costa Rica 2 Hungary 2 Portugal 2 Switzerland 2 Austria 1 Bulgaria 1 Chile 1 Estonia 1 Faroe Islands 1 Lithuania 1 Malta 1 Moldova, Republic of 1 Niger 1 Nigeria 1 Poland 1 San Marino 1 Slovenia 1

Prior to the COVID-19 pandemic almost all IBD clinic was performed face-to-face with virtually zero video consult

During the COVID-19 pandemic face-to-face visits have almost completely disappeared, replace by either phone (the majority) or video consultation

After COVID-19, things will not return to normal. Many face-to-face visits will be replaced by phone or video consultation.

Update Publications

Update Communication

IO IOIB IBD websit ite facelif lift

• sn

sneak previe iew - also check the attached pdf!

• Please send us cool IBD images

related to Endoscopy, Research

• etc. to be used on our website
• Check the current site:

www.ioibd.org

• Also check the current web

statistics with major increase since last month: https://www.ioibd.org/webstat/

JCC and AGA University

• Told Larry Egan we would have articles by

May 8th, 2020

• Review of taskforce articles by publications

committee

• We would like volunteers for reviewing these

to help Corey and co

• Slides of your task force output (basically

slide version of your papers) as soon as possible to have AGA fix and put on website

• Interest in recording audio and/or video for

your slides

Suggested titles for Taskforce output JCC Supplement

• Management of outpatient IBD during COVID—Corey Siegel
• What to do with the hospitalized IBD pt during COVID—David Rubin
• Dialing on telemedicine in IBD—where we were and where we are going-

Uma Mahadevan

• Infusions of IBD medications during a viral pandemic: who comes in, who

stays home, how do we keep our staff safe—Iris Dotan

• Which IBD pts need to be scoped? deciding who gets scoped now, who can

wait, and how to return to normal—Siew Ng

• Clinical trials of IBD medications—global guidance during COVID—Walter

Reinisch

• Can the COVID pandemic serve as a platform for research?- Dermot

McGovern

JCC online supplement – COVID-19 special

• Jointly supported by IOIBD and ECCO
• 7-8 papers including introduction

(±56 pages)

• Online-only
• All articles free to view

AGA University

• AGA University website—open access although requires

creation of log in

• AGA agrees to:
• Provide any required design, clean up, or reformatting of slides (and audio where

applicable)

• Attribute original content creation to IOIBD in partnership with the AGA
• Upload educational content into the AGAU with free access to all learners (no

membership requirement)

• Where possible, include a link to IOIBD’s website in program descriptions
• Promote the educational modules through AGA communications and marketing
• IOIBD agrees to:
• Allow the AGA to add co-branding (AGA logo) to slides – content will be attributed to

IOIBD in partnership with the AGA

• Exclusivity in working with the AGA on this initiative

FDA letter progress

• Letters to agencies sent to:
• EMA
• ANVISA (Brazil)
• Pharmaceuticals and Medical

Devices Agency (PMDA)—Japan

• Waiting for CCF for FDA letter
• Health Canada in cooperation

with Gil Kaplan

Any other business + closing

From now on Monthly Webinars – next: Friday 5 June 2020 Suggestion for Semi-Annual Zoom Meeting for IOIBD members to cover more content in a year Proud of output by IOIBD in such a short

• time. Thank you !!

Stay healthy and safe, be well

COVID-19 and IBD Webinar THANKS FOR JOINING SEE YOU NEXT MONTH!

01 May 2020